Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

23 Apr 2009 08:55

RNS Number : 0351R
ViaLogy PLC
23 April 2009
 



ViaLogy 

VIALOGY ACHIEVES ANOTHER OIL WELL SUCCESS 

LondonApril, 23, 2009. Vialogy (LSE: VIY) announces another successful well in the Galba Prospect in South Central Texas. This well success reinforces operational and commercial validation of the company's QuantumRD™ software-based seismic interpretation service for oil and gas reservoir discovery and characterization. ViaLogy accurately predicted the size, location and formation porosity for this prospect. 

The new producing well, called Mary Ridgeway #1, is located on the Galba lease owned by ViaLogy's partner Atascosa Exploration LLC of San Antonio. The Mary Ridgeway#1 well is estimated to hold larger recoverable reserves compared to ViaLogy's previously announced Cindy Bartlett#2 well discovery announced in March 2009. As before, Vialogy predicted the subsurface hydrocarbon reservoir boundaries, the porosity of the oil-bearing Bartosh sands, formation depth, and positioned the well. Prospect estimates were confirmed by the well-logging and independent subsequent core laboratory analysis. The companies will be releasing actual figures over the next few days, including dollar estimates of recoverable reserves. As announced earlier, under its current contract with Atascosa, Vialogy will receive 5% Back-In-After-Payout working interest in the well. 

As in the previous successful oil find in March, Vialogy's proprietary QuantumRD served as the analytical tool for assessing 3D seismic data sets. The technology exploits subtle variations in seismic noise to overcome limitations in current processing and interpretation techniques, making possible a more accurate analysis of seismic data now in widespread use in the industry. 

Vialogy now turns its attention to its next contracted Atascosa well project, with drilling expected to begin before the end of Q2 2009, and, equally as important, to business opportunities with new customers. Interest in the technology appears considerable. 

Vialogy CEO, Robert W. Dean, said, "This successful well marks a major step forward for the company in demonstrating the capability of QuantumRD and its relevance in the oil patch. Our hope and intention is to enable multiple producing wells in the coming months, cautioning at the same time that no seismic interpretation technique can be one hundred percent effective one hundred percent of the time. What we can bring to the industry over time is a major improvement in the ratio of drilling dry holes to producing wells, and thus considerable cost savings." 

For further information please contact: 

ViaLogy  Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)  Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Atascosa Exploration LLC  John D. Mullins, CEO (+1 210-402-3656)  Nominated Advisor (Seymour Pierce)  Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC  St. Helen's Capital +44 (0) 7628 5582 

About ViaLogy: Network Centric Signal Processing  ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geosiesmology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPUUUACUPBUMW
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.